ARTICLE | Company News
FDA accepts NDA for Aeterna GHD product
January 7, 2014 1:28 AM UTC
Aeterna Zentaris Inc. (TSX:AEZ; NASDAQ:AEZS) said FDA accepted for review an NDA for macimorelin acetate to diagnose adult growth hormone deficiency (GHD). The PDUFA date is Nov. 5. The product is an ...